[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-356536-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-356536-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","mmp14-is-a-safe-target-of-car-t-therapy-against-liver-cancer-and-metastasis-research-open-access","MMP14 is a safe target of CAR-T therapy against liver cancer and metastasis - Research open access","","Liver cancer outcomes remain poor because effective treatments for hepatocellular carcinoma, especially metastatic disease, are still lacking. Chimeric antigen receptor T-cell therapy is promising, yet solid-tumor CAR-T performance is limited by target availability and toxicity risk. This study evaluates CAR-T cells engineered with Peptide G to recognize MMP14 and tests their antitumor efficacy, metastasis suppression via circulating tumor cell elimination, and safety in murine and nonhuman primate models.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/mmp14-is-a-safe-target-of-car-t-therapy-against-liver-cancer-and-metastasis-research-open-access/356536/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/mmp14-is-a-safe-target-of-car-t-therapy-against-liver-cancer-and-metastasis-research-open-access/356536.png","ImageObject",300,407,{"name":42,"@type":43},"\tJames","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",16,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What problem does the study target in liver cancer therapy?","Question",{"text":63,"@type":64},"The study addresses the lack of effective treatments for hepatocellular carcinoma, particularly metastatic HCC, and the limited success of CAR-T therapies in solid tumors due to target and safety constraints.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How are the CAR-T cells designed in this work?",{"text":68,"@type":64},"The CAR-T cells are engineered with Peptide G (PG) to specifically recognize MMP14.",{"name":70,"@type":61,"acceptedAnswer":71},"What evidence supports the therapy’s efficacy and safety?",{"text":72,"@type":64},"PG-CAR-T cells show MMP14-dependent killing in vitro, inhibit liver cancer metastasis by eliminating circulating tumor cells, and demonstrate a favorable safety profile in both mice and nonhuman primates.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},356536,1790196672,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},2336474466412,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Yu etal. Journal of Translational Medicine (2026) 24:424  \n[https://doi.org/10.1186/s12967-026-08036-x](https://doi.org/10.1186/s12967-026-08036-x)  \nJournal of Translational Medicine  \nRESEARCH Open Access  \nMMP14 is a safe target of CAR-T therapy against liver cancer and metastasis  \nYe Yu1,2†, Shirui Zou2†, Jiawei Fan3†, Dong Yang2, Nan Liu2, Zhiyong Bai2, Yongjie Zhu2, Lihong Li4, Dan Cao5, Xudong Zhao2 and Jiaqiong Zou1*  \nAbstract  \nBackground Hepatocellular carcinoma (HCC) is one of the most lethal tumors, and effective treatments for HCC, especially metastatic HCC, are lacking. Chimeric antigen receptor (CAR)-T-cell therapy is considered a promising development in cancer treatment, but to date, CAR-T-cell therapy for solid tumors remains limited. Matrix metalloproteinase 14 (MMP14), the only membrane-bound collagenase, is highly expressed in HCC and other solid tumors and plays critical roles in invasion and metastasis.  \nMethods Here, we aimed to determine whether CAR-T cells targeting MMP14 could effectively treat HCC. CAR-T cells were designed with peptide G (PG) to specifically recognize MMP14 . These cells were evaluated for their cancer-killing efficacy in vitro under MMP14-dependent conditions and tested for antitumor activity in a subcutaneous xenograft liver cancer model. Additionally, a spontaneous liver cancer metastasis model was employed to assess the impact of PG-CAR-T cells on metastasis suppression through circulating tumor cells (CTCs) elimination. The safety profile of PG-CAR-T cells was further investigated in both murine and nonhuman primate models.  \nResults PG-CAR-T cells demonstrated efficient MMP14-dependent killing of cancer cells in vitro and exhibited antitumor effects in the subcutaneous xenograft liver cancer model. In the metastasis model, PG-CAR-T cells significantly inhibited metastasis by eliminating CTCs. Furthermore, PG-CAR-T cells showed a favorable safety profile in both mice and nonhuman primates.  \nConclusion These data support the PG-CAR-T cells for clinical trial of liver cancer. Keywords CAR-T-cell therapy, MMP14, Peptide G, Liver cancer, Metastasis  \n†Ye Yu, Shirui Zou and Jiawei Fan contributed equally to this work.  \n*Correspondence: Jiaqiong Zou [jiaqiongzouxyj@163.com](jiaqiongzouxyj@163.com)  \n1West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan 610041, China  \n2Division of Abdominal Tumor Multimodality Treatment and Laboratory of Cell Engineering & Immunotherapy, Cancer Center and State Key Laboratory of Respiratory Health and Multimorbidity and Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China  \n3General (Specialized) Department, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, Sichuan 610041, China  \n4Kunming Institute of Zoology & National Resource Center for NonHuman Primates, Chinese Academy of Sciences, Kunming,  \nYunnan 650223, China  \n5Division of Abdominal Tumor Multimodality Treatment, Department of Medical Oncology, Cancer Center and State Key Laboratory of Biological Therapy, West China Hospital, Sichuan University, Chengdu,  \nSichuan 610041, China  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s ","cbCairH4Ami762Nw","https://ap.wps.com/l/cbCairH4Ami762Nw","pdf",13196247,18,"English","# Abstract\n# Background\n# Methods\n# Results\n# Conclusion\n# Introduction","[{\"question\":\"What problem does the study target in liver cancer therapy?\",\"answer\":\"The study addresses the lack of effective treatments for hepatocellular carcinoma, particularly metastatic HCC, and the limited success of CAR-T therapies in solid tumors due to target and safety constraints.\"},{\"question\":\"How are the CAR-T cells designed in this work?\",\"answer\":\"The CAR-T cells are engineered with Peptide G (PG) to specifically recognize MMP14.\"},{\"question\":\"What evidence supports the therapy’s efficacy and safety?\",\"answer\":\"PG-CAR-T cells show MMP14-dependent killing in vitro, inhibit liver cancer metastasis by eliminating circulating tumor cells, and demonstrate a favorable safety profile in both mice and nonhuman primates.\"}]","MMP14 is a safe target of CAR-T therapy against liver cancer and metastasis - Research open access | PDF",1790125877,45,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f7008255074395d712a33d761aeffc39.webp",983,1310,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b96103091bfd22cdcaa7d1539267aece.webp",982,1309,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/709c1b627783516574de981ff7dbaaa9.webp",981,1308,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/58d0a990ad38e5447a8d6f489bddf946.webp",980,1306]